Ask a question · get the evidence
We read the clinical trials on GLP-1 weight-loss drugs like Wegovy and Zepbound (and on hair loss, sleep, joints, heart, and memory), then report what they show, in plain English. No spin, no sales pitch.
Browse by topic
Each topic starts from the trials themselves (what was measured, in how many people, and for how long).
Wegovy, Zepbound, Ozempic and Mounjaro. What the trials show on weight, and increasingly on the heart, kidneys, sleep and liver. Our most-studied topic.
Read the evidence →Finasteride, minoxidil and newer options, separating the trial data from the before-and-after photos.
Read the evidence →What works for sleep quality and obstructive sleep apnea, including GLP-1 results from SURMOUNT-OSA.
Read the evidence →Osteoarthritis, supplements and injections (what reduces pain versus what only sounds promising).
Read the evidence →Statins, blood-pressure targets and the cardiovascular data now emerging from weight-loss trials.
Read the evidence →Supplements, diet and lifestyle claims for memory, held to the same standard. What were the trials, really?
Read the evidence →Featured · Coverage
For years the answer was flatly no. A new manufacturer-run bridge program changes the math for some people on Medicare. Here's exactly who qualifies, and for how long.
State Medicaid is a different story: only about 12 of 51 states cover GLP-1s for weight loss. Most still don't.
Read the full breakdown →Updated as new trials land
What the trials show
Headline results from the major GLP-1 outcome trials. Every figure is the number the study reported, nothing rounded up to sound better.
fewer major cardiovascular events (heart attack, stroke, CV death) in adults with heart disease and obesity.
fewer kidney-failure events, cardiovascular events and deaths in people with type-2 diabetes and chronic kidney disease.
of patients had their liver disease (MASH) resolve, versus 34.3% on placebo.
reduction in obstructive sleep-apnea severity in the strongest results, up to about two-thirds.
Results only count if people stay on the drug. Most don't. Here's what real-world data shows.
Sources. Trial results: SELECT, FLOW, ESSENCE and SURMOUNT-OSA as published. Costs: all-in cash prices collected across telehealth routes, 2026. Coverage: Medicare Bridge program terms and a state-by-state Medicaid review. How we read a study →
Why you can trust us
Independence isn't a tagline here. It's the whole business model. If a page ever tries to sell you something, we've failed. Here's the promise, in full: